Predicting local control of choroidal melanomas following 106Ru plaque brachytherapy

Abstract

Tumours that are close to the fovea in young patients appear more likely to show local recurrence. Tumour height >5 mm was the only prognostic factor that determined lack of response. These results may be used to select which tumours require adjuvant therapy.

Endoresection Technique With/Without Brachytherapy for Management of High Posterior Choroidal Melanoma

“…24 The COMS medium tumor study reported a 10.3% 5-year risk of treatment failure using radiotherapy. 25 Recently, Papageorgiou et al 26 In agreement with these authors, we also believe opaque media may contribute to under diagnosis of local recurrence.…”

Management of Uveal Melanoma: A Consensus-Based Provincial Clinical Practice Guideline

“…Brachytherapy provides accurate and continuous administration of radiation and has the added benefit of vision preservation and improved cosmesis 53 . The most commonly used isotopes include 125 I, 103 Pd, and 106 Ru [54][55][56] . The choice of isotope is often based on tumour depth.…”

High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome

“…Minimal but conflicting data have been published; some suggest a better effect when using high dose rate brachytherapy,5 others failed to detect an obvious benefit 6 7. Mössbock et al retrospectively studied 45 patients divided in two apex dose rate groups (seemingly arbitrarily divided in <4 Gy/h or ≥4 Gy/h).…”

“…Recent data suggest that high dose rate ruthenium brachytherapy may be associated with a lower metastatic rate and lower local recurrence rate when dose rate at the tumour apex exceeds 4 Gy/h 5. Results from other reports, however, are conflicting and have not been able to correlate local tumour recurrence with the tumour apex dose rate 6 7…”